# Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion

> **NCT01854996** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-05089771
- **DRUG:** PF-05089771
- **DRUG:** PF-05089771

## Key facts

- **NCT ID:** NCT01854996
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2013-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01854996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01854996, "Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01854996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*